Latrigil (Lamotrigine)

Lamotrigine blocks voltage‑gated sodium channels on neurons, decreasing the release of excitatory neurotransmitters such as glutamate. This stabilises neuronal membranes, reduces abnormal electrical firing, and thereby lowers seizure activity and mood‑related neuronal dysregulation.

The dosage of Latrigil is individualized. A qualified prescriber determines the starting dose, titration schedule, and maintenance dose based on the patient’s condition, age, concomitant therapies, and response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lamotrigine in pregnancy and lactation are limited. It is classified as a drug where benefits must be weighed against potential risks to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative therapies when appropriate.

To request Latrigil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with carbamazepine, another common anticonvulsant, lamotrigine generally has a lower risk of drug‑induced hyponatremia and fewer cognitive side effects, but it requires slower titration to avoid rash. Its efficacy in both focal and generalized seizures makes it a versatile option, though drug‑interaction profiles differ.

Latrigil tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the packaging.

Latrigil is taken orally, usually as a whole tablet swallowed with water. It is typically taken once or twice daily, depending on the prescriber’s titration plan. Patients should not crush, chew, or split the tablet unless specifically instructed.

The most serious adverse reactions include severe skin conditions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, aseptic meningitis, and significant liver injury. Prompt medical attention is required if a rash spreads, blisters develop, or symptoms of meningitis or hepatic dysfunction appear.

Latrigil is contraindicated in individuals with a known hypersensitivity to lamotrigine or any of its excipients. Caution is also advised for patients with a history of severe skin reactions, hepatic impairment, or those taking interacting medications that could markedly alter lamotrigine levels without proper monitoring.